BioCentury
ARTICLE | Clinical News

Inhaled alpha-1 antitrypsin: Phase II data

September 5, 2016 7:00 AM UTC

Top-line data from a double-blind, U.S. Phase II trial in 36 patients with AAT deficiency showed that once-daily 80 and 160 mg doses of inhaled AAT for 12 weeks each met the co-primary endpoints of im...